Seung‐Whan Kim

TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer

Geoffrey R. Oxnard, J.C.-H. Yang, Helena A. Yu et al. · Annals of Oncology · 2020 · 444 citations · Full text

Medicine, Oncology, Pharmacology +14

Role of hypothalamic Foxo1 in the regulation of food intake and energy homeostasis

Min-Seon Kim, Youngmi Kim Pak, Pil‐Geum Jang et al. · Nature Neuroscience · 2006 · 326 citations · Full text

Life Sciences, Nutritional Sciences, Physiology +16

Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis

Vassiliki A. Papadimitrakopoulou, Tony Mok, Ji‐Youn Han et al. · Annals of Oncology · 2020 · 276 citations · Full text

Medicine, Oncology, Pharmacology +15

Essential Role of Mitochondrial Function in Adiponectin Synthesis in Adipocytes

Eun Hee Koh, Joong‐Yeol Park, Hye‐Sun Park et al. · Diabetes · 2007 · 275 citations · Full text

Life Sciences, Endocrinology, Physiology +17

136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial

Myung‐Ju Ahn, James Chih‐Hsin Yang, Helena A. Yu et al. · Journal of Thoracic Oncology · 2016 · 234 citations · Full text

Medicine, Oncology, Pharmacology +13